BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25534957)

  • 21. P16/Ki-67 Dual Staining in Positive Human Papillomavirus DNA Testing for Predictive Diagnosis of Abnormal Cervical Lesions in Northeastern Thai Women.
    Aromseree S; Wongjumpa W; Ekalaksananan T; Temtanakitpaisan A; Kleebkaow P; Srisathaporn S; Tongchai P; Pientong C
    Asian Pac J Cancer Prev; 2022 Oct; 23(10):3405-3411. PubMed ID: 36308365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p16/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China.
    Yu LL; Guo HQ; Lei XQ; Qin Y; Wu ZN; Kang LN; Zhang X; Qiao YL; Chen W
    Oncotarget; 2016 Oct; 7(40):64810-64819. PubMed ID: 27588487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of p16
    Song F; Belinson JL; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    Gynecol Oncol; 2021 Aug; 162(2):322-330. PubMed ID: 34059349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
    Wentzensen N; Fetterman B; Tokugawa D; Schiffman M; Castle PE; Wood SN; Stiemerling E; Poitras N; Lorey T; Kinney W
    Cancer Cytopathol; 2014 Dec; 122(12):914-20. PubMed ID: 25132656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16/ki67 dual staining in the Italian NTCC2 study.
    Benevolo M; Ronco G; Mancuso P; Carozzi F; De Marco L; Allia E; Bisanzi S; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Viti J; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Bonvicini L; Venturelli F; Wentzensen N; Giorgi Rossi P;
    EBioMedicine; 2024 Jun; 104():105149. PubMed ID: 38759278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.
    Luttmer R; Dijkstra MG; Snijders PJ; Berkhof J; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; van Baal WM; Graziosi PG; Quint WG; Spruijt JW; van Dijken DK; Heideman DA; Meijer CJ
    Mod Pathol; 2016 Aug; 29(8):870-8. PubMed ID: 27150161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
    Liu W; Gong J; Xu H; Zhang D; Xia N; Li H; Song K; Lv T; Chen Y; Diao Y; Jao J; Dai S; Zhao P; Yao Q
    Diagn Cytopathol; 2020 Jul; 48(7):635-644. PubMed ID: 32275355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunocytochemical colocalization of P16(INK4a) and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma.
    Singh M; Mockler D; Akalin A; Burke S; Shroyer A; Shroyer KR
    Cancer Cytopathol; 2012 Feb; 120(1):26-34. PubMed ID: 22162342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
    Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M
    Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV16 genotype, p16/Ki-67 dual staining and koilocytic morphology as potential predictors of the clinical outcome for cervical low-grade squamous intraepithelial lesions.
    Vrdoljak-Mozetič D; Krašević M; Verša Ostojić D; Štemberger-Papić S; Rubeša-Mihaljević R; Bubonja-Šonje M
    Cytopathology; 2015 Feb; 26(1):10-8. PubMed ID: 24261348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
    Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL
    Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology.
    Peeters E; Wentzensen N; Bergeron C; Arbyn M
    Cancer Cytopathol; 2019 Mar; 127(3):169-180. PubMed ID: 30811902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study.
    Tsoumpou I; Valasoulis G; Founta C; Kyrgiou M; Nasioutziki M; Daponte A; Koliopoulos G; Malamou-Mitsi V; Karakitsos P; Paraskevaidis E
    Gynecol Oncol; 2011 Apr; 121(1):49-53. PubMed ID: 21194734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical validation of p16/Ki-67 dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial.
    Wright TC; Stoler MH; Ranger-Moore J; Fang Q; Volkir P; Safaeian M; Ridder R
    Int J Cancer; 2022 Feb; 150(3):461-471. PubMed ID: 34536311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.
    Waldstrøm M; Christensen RK; Ørnskov D
    Cancer Cytopathol; 2013 Mar; 121(3):136-45. PubMed ID: 22987560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation the triage performance of p16/Ki-67 dual staining for HR-HPV positive women].
    Jia MM; Zhao DM; Guo Z; Wu ZN; Chen PP; Guo PP; Sun XY; Zhang SK
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Feb; 54(2):192-197. PubMed ID: 32074709
    [No Abstract]   [Full Text] [Related]  

  • 37. Importance of addition of HPV DNA testing to the cytology based cervical cancer screening and triage of findings with p16/Ki67 immunocytochemistry staining in 35 and 45 years old women LIBUSE trial data analysis.
    Sláma J; Dvořák V; Trnková M; Skřivánek A; Hurdálková K; Ovesná P; Nováčková M
    Ceska Gynekol; 2020; 85(6):368-374. PubMed ID: 33711896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
    Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
    J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.
    Wentzensen N; Fetterman B; Castle PE; Schiffman M; Wood SN; Stiemerling E; Tokugawa D; Bodelon C; Poitras N; Lorey T; Kinney W
    J Natl Cancer Inst; 2015 Dec; 107(12):djv257. PubMed ID: 26376685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of p16/Ki-67 adequacy and positivity in HPV-positive women from a screening population.
    Benevolo M; Mancuso P; Allia E; Gustinucci D; Bulletti S; Cesarini E; Carozzi FM; Confortini M; Bisanzi S; Rubino T; Rollo F; Marchi N; Farruggio A; Pusiol T; Venturelli F; Giorgi Rossi P;
    Cancer Cytopathol; 2021 May; 129(5):383-393. PubMed ID: 33142029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.